Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : FDA Advisory Committee Votes -2-

09/18/2021 | 03:40am EDT

Individuals should tell the vaccination provider about all of their medical conditions, including if they:

   -- have any allergies 
 
   -- have had myocarditis (inflammation of the heart muscle) or pericarditis 
      (inflammation of the lining outside the heart) 
 
   -- have a fever 
 
   -- have a bleeding disorder or are on a blood thinner 
 
   -- are immunocompromised or are on a medicine that affects the immune system 
 
   -- are pregnant, plan to become pregnant, or are breastfeeding 
 
   -- have received another COVID-19 vaccine 
 
   -- have ever fainted in association with an injection 

The vaccine may not protect everyone.

Side effects reported with the vaccine include:

   -- There is a remote chance that the vaccine could cause a severe allergic 
      reaction 
 
          -- A severe allergic reaction would usually occur within a few 
             minutes to one hour after getting a dose of the vaccine. For this 
             reason, vaccination providers may ask individuals to stay at the 
             place where they received the vaccine for monitoring after 
             vaccination 
 
          -- Signs of a severe allergic reaction can include difficulty 
             breathing, swelling of the face and throat, a fast heartbeat, a 
             bad rash all over the body, dizziness, and weakness 
 
          -- If an individual experiences a severe allergic reaction, they 
             should call 9-1-1 or go to the nearest hospital 
 
   -- Myocarditis (inflammation of the heart muscle) and pericarditis 
      (inflammation of the lining outside the heart) have occurred in some 
      people who have received the vaccine. In most of these people, symptoms 
      began within a few days following receipt of the second dose of the 
      vaccine. The chance of having this occur is very low. Individuals should 
      seek medical attention right away if they have any of the following 
      symptoms after receiving the vaccine: 
 
          -- chest pain 
 
          -- shortness of breath 
 
          -- feelings of having a fast-beating, fluttering, or pounding heart 
 
   -- Side effects that have been reported with the vaccine include: 
 
          -- severe allergic reactions; non-severe allergic reactions such as 
             rash, itching, hives, or swelling of the face; myocarditis 
             (inflammation of the heart muscle); pericarditis (inflammation of 
             the lining outside the heart); injection site pain; tiredness; 
             headache; muscle pain; chills; joint pain; fever; injection site 
             swelling; injection site redness; nausea; feeling unwell; swollen 
             lymph nodes (lymphadenopathy); diarrhea; vomiting; arm pain 
 
   -- These may not be all the possible side effects of the vaccine. Serious 
      and unexpected side effects may occur. The vaccine is still being studied 
      in clinical trials. Call the vaccination provider or healthcare provider 
      about bothersome side effects or side effects that do not go away 

There is no information on the use of the vaccine with other vaccines.

Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit https://www.globenewswire.com/Tracker?data=cqMoKZXGH82cJZP8ILzrrixE9H0PTNpl_1Xw4COIb0hneZCe9fld0g_4okfYf9FnPlKRu7I3TtSvplt7b08efIZugsM_sWG1H9Si-YMbWDVlYI5IL4zEcvMhEDpiRoxjUcyMYUDcHdJSyxH9uWHhuliAnE0lR9GtkPFM3Ltdmoma5yTSnFtZcPn_GtAFE8EGbXbqqpVsJ929QBF72PI-od4J8fokyUqZC1wu8w7sklTq1agoSuW0jYS-12T_5sO-_YeB266HBFd9srizV3DeOmJGk_1-uSIfR8LBeIenTqjhnugjE3aVUDvVRBwuHh20 http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at https://www.globenewswire.com/Tracker?data=I_ZXFvkayYcxAO9D6yueBdXKEZ4M5_-IbN3yLxDwCyApKck_R48I91kwpzQeF7-aPCRkQhTuk_Zyo0VlGKjZ0eD_E9jwfkqrt4VhYjhqjZ1tkWuspEcuJfrDILH48H_AaxouqQxW2hvGkRCB3VryQKMa8MUfttm5txxkkRKnt8QMx1LOjPX9RXjIeP5PE-RLUTPcrWvEYpCcKK3q6PK5pFOU9JRy_R0DaETz_0zNee4yvjfNV7GZSLj54rTN82dHWSDVVLEcS2B1QQTly04ojQpHFgHHxuHdxb2zRLZnebIcNAk2i4fE5q6LkQkSdkRo3qtEKEdTcI1ThNQXS5j5ig== www.pfizersafetyreporting.com or by calling 1-800-438-1985.

Please https://www.globenewswire.com/Tracker?data=ZlJrZ6h7-K8kRq_TUZQiR_iS3K8aU4XNVTUiNVTwOhL-ik1hQyFsNRUcJG67VAR-KgV-mhP8CvzNhwSIEA0QW8Nej8Oo5mAs2GHeN-_4BfdpS-h2csMBSNGFU2hWEFO26rn6_emTZUV0-HkVHp3ilyZQJlHUHG6_Dcxp_oyYmrfPbGHMkBTkB1UYSc4eGjEa1PYY50SFcjQeZxBNIdn4oh1GkAQ0YZQrEgS-YEpj421M05nHuLqrW13xEDAqXmuJDrtzl4BYN2iBFL5JgBngMVWrT7LjN-DqwEYKropIbLfjX9B9hTTtqN6OwHfav86TCSB3VyAX-T3ux63kO8yUOw== click here for full Prescribing Information (16+ years of age). Please https://www.globenewswire.com/Tracker?data=ZlJrZ6h7-K8kRq_TUZQiR3-qIAoiHuvDPycWX4ohVTX49R1uMFnO5_OGKGr7nh7YaawMFl-vOQSsDb3COQgfeL0aZgIEf8FMroROEpGXCgxdg1lNXCRoimNuoQZpU4EoEwdLyzIQSlnlYthVfrJ43aN_-8mt9w5cM8Len2mq6dSw4eN5GaL-sudreSo4JXgJYcsg-dJGigVZJSuZFDF34Nny8mY7rCup2hm1qxbnnyIWffCP-Xhza9OFRxRDTOE_IekMwW006vweddyh1W185Q3SCVQFdR5xx1QebTESVvg8YYz4635Hp0Of2FUgxaGksZ9fvhaonoWcMFuo-agRNw== click here for Fact Sheet for Vaccination Providers (12+ years of age).

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at https://www.globenewswire.com/Tracker?data=I_ZXFvkayYcxAO9D6yueBW9HY3cmptuRyyOktWDFlbFicw16FTKTQ-CAr-CCkqHjVdJhqoQ6yKaBctwOU5tUx8L01cPvcl6q0PtN3iw61EmqSuWSpV6QgJPGFGajFvczzBaHbwpt76-9mXYcMBCECgQPFcrIXPKL4DdumJSrOV547flfgSXvoiIv7NgCE5g2luA8gvmQfOVTg-ilKtN2orFqRfmkidoFsPtULi0dkuZ9oW_j1koQPw0vjUwkdPA_i2kcD_v6-zQ_NXXNm5FBSAUgPcDtz3SeFqBMXCTGcLk= www.Pfizer.com. In addition, to learn more, please visit us on https://www.globenewswire.com/Tracker?data=I_ZXFvkayYcxAO9D6yueBZo1YzbxWpPPExN8kKi9MmHqNOfr9B0NVOf1zCVd9BOP0kRVVu91tPM7pyMZ5hS14ivfiNppy_Xq1NwIb6HQ4JwFo_JSTQGPStSdNJsKT0Xpxi0EyYfy3Xi9fUbRwx7Dp8MqljBzD8HzGD6-ts4MLG3CID8lxjfW_bGYnPkS0lBoOpB_EwLQpDt3nROdQt6XaZIeeJofV3Wq54GcLGD91oZrSdQXzEKcwCFaR6Y56lCyiZRbcEftqOLHbIMfqPNCvfZB0XJg-m8lFbdCFcu5igI= www.Pfizer.com and follow us on Twitter at https://www.globenewswire.com/Tracker?data=U4k7Xoa5gUH_SddaZhFYLLqh0mEuKEWYDZNcTamLQWtopmTNfpK0s-vVqPVNtevkGp5CSiiJFcA_2HI3uwjelZLCNEytOKbx1_IR7HDK_B2F9S3OiOkVso7LFdkBEDRS2NASQ3UNgm1bI5shq298NvQ3hrcc9Pk8orzMWn7g97xrYPG39-RDitgCzATZRC6LMgMPsVV81yjOaFUdjDS9BPR025z3crHFHWY-XCPNa0OnrXJsnbQM7ZTavhUYWGO9d4BowO8L26grQD_1u4kYng== @Pfizer and https://www.globenewswire.com/Tracker?data=U4k7Xoa5gUH_SddaZhFYLPe6fViBJs5lk2fHVXVg-UUbDrgMzM__2Wsrs7GZYSCziQGt02Hma_FOE-PjhPueaAwQRgbtqVl_qmglWcrMKc5zkOEon_egYxJWnKJyIxDNjDW1E8QtkVouavEed9I597Jp3vH8sVrN2ePydeW126oPypQHQ-GkNpL4x5Nhp4hjpXrj9FSlnS-YDT6odQ83oh01ekUHIpStCj1uU7bCmnq4jXPuPMMfGXNwJeNG__XS7Jl6RSdcWryDwQ5VXPOvhYPnNEwlopUZ-Hu0T6OTP9U= @Pfizer News, https://www.globenewswire.com/Tracker?data=yjB8pDe3eZ6QqRFMxqohhpJjgTRQRQDARUlVRTrBY6sI_CoEVAVhMy6Iy1vWVlJLuvboMvaoqsBvlfxDkoQYZUpkSEOBRA1NLS5M3LEmEGEH3hRqdzLeXZAMSOx5l9-uwZcUqMQp6IjZCJ52Y30xpoFZz0h-l2QKunG7ayNy6c9Jo3fe9um73H6ggF018Lv3iZAVJmTwp-tq20SQ4n_-_KiDHIMF1jUV0eGUJjWvseKoZ7O8wbBc2AVaUKsJpAuvbSWA3ax-svX5UOMqCVMojmCt9VGCU1hVZto-hYJh2sI= LinkedIn, https://www.globenewswire.com/Tracker?data=Zt6JCFMAgE2O99P0HZsnpsWbfn3uH5l8B_vUP7NkJfdcgvbDsVirndAO-s3tu9natCMtODbyhI5Lsxvee3gMgC7M_KrxycKQNDKuTUqwqgG0AHIc7eGTBvaVOhg9SfKJy1XejD8EMC_Yw7DPq2vSGqkdWmMRi8wjob7BJeP7PChbwcupP1nGSnrMPehVWe5lp8NHLqPJxhouO1VixbiheqPSwtQnbkL7PiEox34z03HnTXPGXlyrVVWed6BY0Opmc0oNoeiTv3qVOqQ6MLD0aF92y2UPL0eMpPev8iL_aSU= YouTube and like us on Facebook at https://www.globenewswire.com/Tracker?data=vSuEsC59M97PG99MgkAADWrnUyDp1YgxHNv_f1v6ylPR6xaai7egb_Lr-DKEl5977-82voU9tA3HcoymsC8XNx5PVLl5GaPguAXEAq_-QZv61jifXxM6AGOAVBjn7a9oQVgWnIyRp7Ad1i-WKk1KrvCjb_bOcIcljg7C2ozuC7BP7g7wxgEbko1qo1zqJNMQXtVGsdLE9689GUnTN6F9AQ5_-ua3mGkqr9G-ZthcAsE-ul2uItFzhlEziWfagjW4BwFoYFdldOBkPcCC1ugvsrwqTMU6G8jWk1M_djZtIofn7cL3QrD4W5tDpkaqX4Tg Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer's efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical

(MORE TO FOLLOW) Dow Jones Newswires

September 18, 2021 03:40 ET (07:40 GMT)

All news about BIONTECH SE
05:00pHealth Care Up On Defensive Bias -- Health Care Roundup
DJ
03:32pMODERNA : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines ma..
RE
01:45pWalmart, Walgreens U.S. stores roll out Moderna, J&J COVID-19 booster shots
RE
11:27aPFIZER : FDA Panel to Vote on Pfizer COVID-19 Shots for Kids; Data Shows Vaccine 90.7% Eff..
MT
11:10aEuropean ADRs Move Higher in Friday Trading
MT
11:07aPFIZER : Norway Stops Second Dose COVID-19 Vaccine Inoculations For Minors
MT
10:58aPFIZER : BioNTech COVID-19 Vaccine Shows Nearly 91% Efficacy in Kids
MT
10:54aBIONTECH : Deutsche Bank Starts BioNTech at Hold with $250 Price Target
MT
10:28aPFIZER : BioNTech COVID Vaccine Reportedly Shows Nearly 91% Efficacy in Kids
MT
10/21Health Care Up As BioNTech Rallies -- Health Care Roundup
DJ
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 16 703 M 19 454 M 19 454 M
Net income 2021 8 797 M 10 245 M 10 245 M
Net cash 2021 8 661 M 10 088 M 10 088 M
P/E ratio 2021 7,92x
Yield 2021 -
Capitalization 67 225 M 67 225 M 78 297 M
EV / Sales 2021 3,51x
EV / Sales 2022 2,89x
Nbr of Employees 2 500
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 278,34 €
Average target price 254,57 €
Spread / Average Target -8,54%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE251.28%69 162
GILEAD SCIENCES, INC.14.98%83 993
WUXI APPTEC CO., LTD.24.51%65 142
REGENERON PHARMACEUTICALS17.86%59 196
VERTEX PHARMACEUTICALS-20.84%48 536
BEIGENE, LTD.45.24%35 024